LCTX: כמות מזומנים למניה Lineage Corp

Lineage Cell Therapeutics - לוגו גרפי של המנפיק LCTX

Compliance with biomaterial disposal standards minimizes the environmental footprint of Lineage Cell Therapeutics (LCTX), which correlates with the cash-per-share trend. The 0.18 level indicates the status of the liquidity parameter. The development of cell-based therapies for vision and the CNS expands the company's reach within the regenerative market. High staff qualification is maintained through stock option programs tied to clinical trial results.

מזומנים למניה: Lineage Cell Therapeutics (LCTX) עבור 04.07.2022 - 20.11.2026

פילוחים אנליטיים של חברת Lineage Cell Therapeutics

- מחיר שוק ויעדי מחיר של אנליסטים:
- מדדי זמינות כספים ותזרימי מזומנים:
ניתוח כללי של החברה:Lineage Cell Therapeutics - LCTX
פריט של המותג lineagecell.com

For Lineage Cell Therapeutics (LCTX), which invests in the commercialization of cell technologies for treating oncology and degenerative diseases, maintaining a liquidity reserve is critical for funding prolonged R&D cycles. The trend in cash per share reflects the ratio of total cash to the number of common shares, determining the fundamental level of business protection against macroeconomic shocks and the real value of a single ownership stake.